Skip to content
AiSeekAiSeek
Sign in
Teva Pharmaceuticals Announces FDA Approval of WELTRUZA™ for Monthly Injectable Olanzapine for SchizophreniaAI illustration
NewHealthPolicyScienceReported 2026-10-09 19:00

Teva Pharmaceuticals Announces FDA Approval of WELTRUZA™ for Monthly Injectable Olanzapine for Schizophrenia

Teva Pharmaceuticals has received FDA approval for WELTRUZA™, a once-monthly subcutaneous long-acting injectable (LAI) formulation of olanzapine for treating schizophrenia in adults, marking the first of its kind with no loading doses, oral supplementation, or post-injection monitoring required.

In depthRead the in-depth story

Why it matters. Patients with schizophrenia now have a new, more convenient treatment option that could improve adherence and long-term symptom management.

01

Evidence

  • GGlobeNewswire public company newsCompany2026-10-09 19:00
    For period one of the study (first 8 weeks), 675 patients were randomized to receive a subcutaneous injection of once-monthly olanzapine LAI (WELTRUZA) (low, medium or high dose) or placebo in a 1:1:1:1 ratio.
    View source